融资方面，南模生物当日融资买入403.02万元。当前融资余额6368.59万元，占流通市值的1.94%，融资 余额超过近一年60%分位水平，处于较高位。 机构持仓方面，截止2025年9月30日，南模生物十大流通股东中，天弘医疗健康A（001558）位居第十 大流通股东，持股37.74万股，为新进股东。融通健康产业灵活配置混合A/B（000727）退出十大流通股 东之列。 融券方面，南模生物12月24日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 12月24日，南模生物涨0.86%，成交额2025.20万元。两融数据显示，当日南模生物获融资买入额403.02 万元，融资偿还446.37万元，融资净买入-43.35万元。截至12月24日，南模生物融资融券余额合计 6368.59万元。 分红方面，南模生物A股上市后累计派现3004.13万元。近三年，累计派现1000.47万元。 资料显示，上海南方模式生物科技股份有限公司位于上海市浦东新区琥珀路63弄1号，成立日期2000年9 月20日 ...

证券代码：688265 证券简称：南模生物 公告编号：2025-071 上海南方模式生物科技股份有限公司 关于回购股份减持时间届满未减持股份的结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份的基本情况 ■ 上述减持主体无一致行动人。 二、减持计划的实施结果 （一）股东因以下事项披露减持计划实施结果： 披露的减持时间区间届满 本次减持计划期间内，上海南方模式生物科技股份有限公司回购专用证券账户未实施减持。 上海南方模式生物科技股份有限公司（以下简称"公司"）于2024年2月23日至2024年5月22日期间通过集 中竞价交易方式累计回购股份788,912股，占公司总股本的1.0119%。前述回购的股份拟用于维护公司价 值及股东权益，将在披露回购实施结果公告（即2024年5月23日）12个月后采用集中竞价的方式出售， 并在披露股份回购实施结果公告日后3年内完成转让；若公司未能在上述期限内完成转让，尚未转让的 已回购股份将予以注销。 ● 减持计划的实施结果情况 2025年8月29日， ...

证券代码：688265 证券简称：南模生物 公告编号：2025-071 回购股份的基本情况 上海南方模式生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 23 日至 2024 年 5 月 22 日期间通过集中竞价交易方式累计回购股份 788,912 股， 占公司总股本的 1.0119%。前述回购的股份拟用于维护公司价值及股东权益，将 在披露回购实施结果公告（即 2024 年 5 月 23 日）12 个月后采用集中竞价的方 式出售，并在披露股份回购实施结果公告日后 3 年内完成转让；若公司未能在上 述期限内完成转让，尚未转让的已回购股份将予以注销。 减持计划的实施结果情况 2025 年 8 月 29 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《关于回购股份集中竞价减持股份计划公告》（公告编号：2025-054），公司计 划按照市场价格，通过集中竞价交易方式减持回购股份合计不超过 779,635 股 （不超过公司总股本的 1%），减持期间为自前述公告披露之日起 15 个交易日后 的 3 个月内。若减持期间公司发生派发红利、送红股、转增股本、增发新股、配 股等导致股份变动事 ...

证券日报网讯 12月2日晚间，南模生物发布公告称，截至2025年11月30日，公司尚未减持已回购股份。 （文章来源：证券日报） ...

证券代码：688265 证券简称：南模生物 公告编号：2025-070 上海南方模式生物科技股份有限公司 关于回购股份集中竞价减持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 回购股份的基本情况 上海南方模式生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 23 日至 2024 年 5 月 22 日期间通过集中竞价交易方式累计回购股份 788,912 股，占 公司总股本的 1.0119%。前述回购的股份拟用于维护公司价值及股东权益，将在 披露回购实施结果公告（即 2024 年 5 月 23 日）12 个月后采用集中竞价的方式 出售，并在披露股份回购实施结果公告日后 3 年内完成转让；若公司未能在上述 期限内完成转让，尚未转让的已回购股份将予以注销。 减持计划的进展情况 2025 年 8 月 29 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《关于回购股份集中竞价减持股份计划公告》（公告编号：2025-054），公司计划 按照市场价格，通过集 ...

Core Viewpoint - Nanmo Biology focuses on the research, production, sales, and related technical services of genetically modified animal models, primarily using mice, rats, and nematodes as model organisms [1] Company Overview - The company utilizes gene editing technology to insert, delete, or modify endogenous genes, creating biological models that simulate specific physiological, pathological, and cellular characteristics of humans [1] - The genetically modified animal models produced by the company mainly refer to genetically modified mouse models [1] Strategic Positioning - The company does not engage in any technical collaboration or strategic partnership with Yizhiming [1]

证券日报网讯南模生物11月25日在互动平台回答投资者提问时表示，公司截至2025年6月30日股东总数 为6，522户；截至2025年9月30日股东总数为6，687户。 （文章来源：证券日报） ...

Core Viewpoint - Nanmo Biology (688265.SH) focuses on the research, production, sales, and related technical services of genetically modified animal models, primarily using mice, rats, and nematodes as model organisms [1] Group 1: Company Overview - The company utilizes gene editing technology to insert, delete, or modify specific DNA segments, creating biological models that simulate human physiological, pathological, and cellular characteristics [1] - The genetically modified animal models produced by the company mainly refer to genetically modified mouse models [1] Group 2: Strategic Positioning - The company does not engage in any technical collaboration or strategic partnership with Yizhiming [1]

Core Viewpoint - Nanmo Bio has experienced significant stock price fluctuations in 2023, with a year-to-date increase of 79.28% but recent declines in the short term [1] Company Overview - Nanmo Bio, officially known as Shanghai Nanmo Biological Technology Co., Ltd., was established on September 20, 2000, and went public on December 28, 2021 [1] - The company specializes in the research, production, and sales of genetically modified animal models and related technical services [1] - Revenue composition includes standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and others (0.91%) [1] Financial Performance - For the period from January to September 2025, Nanmo Bio reported a revenue of 303 million yuan, representing a year-on-year growth of 14.29% [2] - The net profit attributable to shareholders reached 26.76 million yuan, showing a substantial year-on-year increase of 276.14% [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 2.53% to 6,687, while the average circulating shares per person decreased by 2.47% to 11,658 shares [2] - Since its A-share listing, Nanmo Bio has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Tianhong Medical Health A is a new entrant, holding 377,400 shares [3]

Group 1 - The core viewpoint of the news is that Nanmo Biotechnology experienced a decline in stock price and significant financing activity, indicating a high level of market interest and potential volatility [1] - On November 12, Nanmo Biotechnology's stock fell by 1.59%, with a trading volume of 53.85 million yuan. The net financing buy was -10.10 million yuan, with a total financing balance of 57.63 million yuan, accounting for 1.68% of the circulating market value [1] - The company has a high financing balance, exceeding the 60th percentile of the past year, indicating a relatively elevated level of leverage in the market [1] Group 2 - As of September 30, the number of shareholders for Nanmo Biotechnology increased by 2.53% to 6,687, while the average circulating shares per person decreased by 2.47% to 11,658 shares [2] - For the period from January to September 2025, Nanmo Biotechnology reported a revenue of 303 million yuan, representing a year-on-year growth of 14.29%, and a net profit attributable to shareholders of 26.76 million yuan, which is a significant increase of 276.14% year-on-year [2] Group 3 - Since its A-share listing, Nanmo Biotechnology has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3] - As of September 30, 2025, Tianhong Medical Health A became the tenth largest circulating shareholder with 377,400 shares, while a previous major shareholder, Rongtong Health Industry Flexible Allocation Mixed A/B, exited the top ten list [3]